BELGRADE, MT / ACCESSWIRE / April 2, 2018 / Xtant™ Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products

BELGRADE, MT / ACCESSWIRE / March 27, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products

Reports Pro Forma Stockholders’ Equity of approximately $47.4M as of 2/15/18 Xtant has regained compliance with the NYSE American listing standards BELGRADE, Mont., Feb. 15,

Exchange of $70.238M (plus interest) of convertible notes into 10,401,309 shares of common stock at $7.20 per share. $6.809M Private Placement representing 945,819 shares of

Approval of the issuance of new shares of common stock, as required by the NYSE American. Approval of an amendment to its certificate of incorporation,

Conversion of $1.627M (plus interest) of convertible notes into common stock Exchange of $70.238M (plus interest) of convertible notes into common stock Upon stockholder approval,

Company restructuring efforts continue to gain traction towards profitability Third Quarter 2017 Highlights Reported third quarter 2017 revenue of $19.8 million compared to $23.1 million

BELGRADE, Mont., Nov. 09, 2017 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical

BELGRADE, Mont., Nov. 01, 2017 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical

BELGRADE, Mont., Oct. 27, 2017 (GLOBE NEWSWIRE) — Xtant Medical Holdings, Inc. (NYSE American:XTNT), a leader in the development of regenerative medicine products and medical